Roche raises its outlook as momentum lasts after Q3 stronger base

BUY-Top Picks, Fair Value CHF327 (+29%)
News published on October Thursday 22, 2015
Share on

Roche posted a solid quarter that came in about CHF100m above expectations, driven by Perjeta and Mircera in the Pharmaceutical division. Both divisions grew 6% CER. Outlook for revenue growth in 2015 is raised to mid-single digit although this should not drive meaningful CS revisions. In conclusion, slightly better than expected figures in Q3 but limited impact on CS numbers to be expected.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities